Cerevel Therapeutics Stock Forecast, Price & News

+0.16 (+1.27 %)
(As of 06/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume310,668 shs
Average Volume242,159 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CERE News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Cerevel Therapeutics logo

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.95 out of 5 stars

Medical Sector

103rd out of 2,105 stocks

Pharmaceutical Preparations Industry

44th out of 832 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cerevel Therapeutics (NASDAQ:CERE) Frequently Asked Questions

Is Cerevel Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cerevel Therapeutics stock.
View analyst ratings for Cerevel Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Cerevel Therapeutics?

Wall Street analysts have given Cerevel Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cerevel Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) announced its quarterly earnings results on Sunday, May, 16th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.01.
View Cerevel Therapeutics' earnings history

What price target have analysts set for CERE?

5 equities research analysts have issued 1-year price targets for Cerevel Therapeutics' stock. Their forecasts range from $17.00 to $27.00. On average, they anticipate Cerevel Therapeutics' stock price to reach $21.50 in the next year. This suggests a possible upside of 69.0% from the stock's current price.
View analysts' price targets for Cerevel Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cerevel Therapeutics' key executives?

Cerevel Therapeutics' management team includes the following people:
  • Dr. N. Anthony Coles Jr., CEO & Exec. Chairman (Age 61, Pay $1.24M)
  • Dr. John J. Renger Ph.D., Chief Scientific Officer (Age 52, Pay $945.08k)
  • Ms. Kathleen Tregoning M.A., Chief Corp. Affairs Officer (Age 50, Pay $600.79k)
  • Mr. Abraham N. Ceesay, Pres (Age 43)
  • Ms. Kathy Y. Yi M.B.A., Chief Financial Officer (Age 49)
  • Mr. Mark Bodenrader, VP of Fin. & Chief Accounting Officer (Age 48)
  • Mr. Matthew Calistri, VP of Investor Relations
  • Mr. Kenneth A. DiPietro, Chief HR Officer (Age 62)
  • Dr. Ramiro Sanchez, Chief Medical Officer (Age 60)

Who are some of Cerevel Therapeutics' key competitors?

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), (ANRZQ) (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).

What is Cerevel Therapeutics' stock symbol?

Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE."

Who are Cerevel Therapeutics' major shareholders?

Cerevel Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (3.64%), Price T Rowe Associates Inc. MD (2.67%), Federated Hermes Inc. (1.53%), Ally Bridge Group NY LLC (1.36%), Citadel Advisors LLC (0.96%) and BlackRock Inc. (0.86%).
View institutional ownership trends for Cerevel Therapeutics

Which institutional investors are selling Cerevel Therapeutics stock?

CERE stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Citadel Advisors LLC, Ally Bridge Group NY LLC, Geode Capital Management LLC, Brookfield Asset Management Inc., Morgan Stanley, Penserra Capital Management LLC, and UBS Group AG.
View insider buying and selling activity for Cerevel Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Cerevel Therapeutics stock?

CERE stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Bank of New York Mellon Corp, Woodline Partners LP, Millennium Management LLC, Verition Fund Management LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., and Sphera Funds Management LTD..
View insider buying and selling activity for Cerevel Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cerevel Therapeutics?

Shares of CERE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerevel Therapeutics' stock price today?

One share of CERE stock can currently be purchased for approximately $12.72.

How much money does Cerevel Therapeutics make?

Cerevel Therapeutics has a market capitalization of $1.62 billion. The biotechnology company earns $-152,140,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does Cerevel Therapeutics have?

Cerevel Therapeutics employs 104 workers across the globe.

What is Cerevel Therapeutics' official website?

The official website for Cerevel Therapeutics is

Where are Cerevel Therapeutics' headquarters?

Cerevel Therapeutics is headquartered at 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States.

How can I contact Cerevel Therapeutics?

Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The biotechnology company can be reached via phone at +1-805-3766500 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.